Skip to main content
AstraZeneca PLC logo

AstraZeneca PLC — Investor Relations & Filings

Ticker · AZN ISIN · GB0009895292 LEI · PY6ZZQWO2IZFZC3IOL08 IL Manufacturing
Open in API
Filings indexed 3,411 across all filing types
Latest filing 2022-11-23 Director's Dealing
Country GB United Kingdom
Listing IL AZN

About AstraZeneca PLC

https://www.astrazeneca.com/

AstraZeneca PLC is a global, science-led biopharmaceutical company that focuses on the discovery, development, and commercialization of prescription medicines. The company's portfolio is concentrated on several main therapy areas, including Oncology; Cardiovascular, Renal & Metabolism; and Respiratory & Immunology. AstraZeneca is committed to advancing healthcare through a robust research and development pipeline, aiming to deliver innovative medicines that address significant unmet medical needs for millions of patients worldwide. The company leverages scientific innovation to transform the future of healthcare and improve patient outcomes.

Recent filings

Filing Released Lang Actions
DIRECTOR/PDMR SHAREHOLDING
Director's Dealing Classification · 100% confidence The document is a Form 6-K filed with the SEC by AstraZeneca PLC, reporting a transaction in the company's shares by a director (Chief Financial Officer). It details the sale of American Depositary Shares by a Person Discharging Managerial Responsibilities (PDMR). The content focuses on insider share transactions and notifications required under market abuse regulations. There are no financial statements, earnings data, or management discussion. The document is a regulatory announcement of a director's dealing in shares, fitting the category of Director's Dealing (DIRS). The document length is 4460 characters, which is consistent with a detailed insider transaction report rather than a full financial report or announcement of a report publication.
2022-11-23 English
Director/PDMR Shareholding
Director's Dealing Classification · 100% confidence The document is an official notification filed via RNS (RNS Number: 3962H) concerning a 'Transaction by Person Discharging Managerial Responsibilities' (PDMR). Specifically, it details the sale of American Depositary Shares (ADSs) by the Chief Financial Officer, Aradhana Sarin. This type of filing, reporting personal share transactions by directors and executives, directly corresponds to the definition of 'Director's Dealing' (Code: DIRS). Although it is distributed via RNS, the specific content mandates the DIRS classification over the general RNS fallback.
2022-11-23 English
ENHERTU RECOMMENDED FOR EU APPROVAL IN GASTRIC
Regulatory Filings Classification · 95% confidence The document is a Form 6-K filing by AstraZeneca PLC, which is a report of a foreign issuer pursuant to the Securities Exchange Act of 1934. It contains detailed information about the recommendation for EU approval of Enhertu for gastric cancer, including clinical trial results, regulatory status, and drug development updates. Form 6-K filings are typically used by foreign private issuers to report material information that is not required to be reported on Forms 20-F or 40-F. This document is not an annual report, earnings release, or any other specific financial report but rather a regulatory filing providing material corporate and product development information. Therefore, the appropriate classification is Regulatory Filings (RNS). The document length is substantial (15,000 characters), and it contains substantive information rather than just an announcement or certification, supporting this classification with high confidence.
2022-11-14 English
IMFINZI RECOMMENDED FOR APPROVAL IN THE EU FOR BTC
Regulatory Filings Classification · 95% confidence The document is a Form 6-K filing by AstraZeneca PLC, which is a report of a foreign issuer pursuant to the Securities Exchange Act of 1934. It provides detailed information about the recommendation for approval of Imfinzi in the EU for biliary tract cancer, including clinical trial results, regulatory status, and company background. The document is not an annual or quarterly report, nor is it an earnings release or management discussion. It is a regulatory announcement providing material information about a product approval recommendation. Form 6-K filings are typically classified as Regulatory Filings (RNS) because they are periodic reports submitted by foreign private issuers to the SEC to disclose material information. The document is lengthy (over 12,000 characters) and contains substantive information but does not fit into other specific categories such as earnings, M&A, or governance. Therefore, the appropriate classification is Regulatory Filings (RNS).
2022-11-14 English
LYNPARZA COMBO RECOMMENDED IN THE EU FOR MCRPC
Regulatory Filings Classification · 95% confidence The document is a Form 6-K filing by AstraZeneca PLC, which is a report of a foreign issuer pursuant to the Securities Exchange Act of 1934. It contains detailed information about a regulatory recommendation for a drug combination (Lynparza combo) in the EU for metastatic castration-resistant prostate cancer (mCRPC). The document includes clinical trial results, drug approval status, and company collaboration details. It is not an annual or quarterly financial report, nor is it an earnings release or management discussion. It is a regulatory announcement providing material information about the company's product development and regulatory status. Form 6-K filings are typically classified as Regulatory Filings (RNS) because they are periodic reports submitted by foreign private issuers to disclose material information to the SEC and investors. The document is substantive and lengthy (15,000 characters), but it does not contain financial statements or detailed financial analysis. Therefore, the appropriate classification is Regulatory Filings (RNS).
2022-11-14 English
IMFINZI + IMJUDO APPROVED IN US FOR LUNG CANCER
Regulatory Filings Classification · 95% confidence The document is a Form 6-K filing by AstraZeneca PLC, which is a report of a foreign issuer pursuant to the Securities Exchange Act of 1934. It provides detailed information about the FDA approval of a new treatment combination for metastatic non-small cell lung cancer, including clinical trial results and company commentary. The document is not an annual or quarterly financial report, nor is it an earnings release or management discussion. It is a regulatory filing providing material information about a significant corporate event (drug approval and clinical trial results). The document is lengthy (over 14,000 characters) and contains substantive information, not just an announcement of a report. Since Form 6-K filings are typically regulatory filings for foreign issuers to disclose material information, and this document does not fit into other specific categories such as earnings release, M&A, or capital update, the most appropriate classification is Regulatory Filings (RNS).
2022-11-14 English

Browse filings by year

34 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.